Background. We analysed in a carefully phenotyped cohort of paediatric patients the association of serum angiotensin II type 1 receptor antibodies (AT 1 R-Ab) with specific histological lesions and with graft function and survival in conjunction with overall and complement-binding donor-specific human leucocyte antigen donor-specific antibodies (HLA-DSA). Methods. Sera of 62 patients at the time of renal graft biopsy for clinical indication >1 year post-transplant were assessed for AT 1 R-Ab by enzyme-linked immunosorbent assay (ELISA) and for DSA and C1q-fixing DSA by single-antigen bead technology. Results. Serum AT 1 R-Ab concentration was significantly higher in antibody-mediated rejection (ABMR) than in T-cell-mediated rejection or control. By receiver operating characteristic (ROC) curve analysis, the optimal AT 1 R-Ab cut-off value discriminating between patients with features of ABMR and those without was 9.5 U/mL. A total of 6 of 28 patients (21.4%) with ABMR were only positive for AT 1 R-Ab. Patients with AT 1 R-Ab and HLA-DSA double positivity had a significantly higher vascular microinflammation score than DSA-negative patients. The 5-year graft survival was only 59% in the AT 1 R-Ab-positive group compared with 87% in the AT 1 R-Ab-negative group. Patients with AT 1 RAb and HLA-DSA double positivity tended to have a more rapid decline of estimated glomerular filtration rate (eGFR) than patients who were only positive for AT 1 R-Ab or HLA-DSA. In a multivariate Cox regression model of non-invasive factors, C1q-positive HLA-DSA, eGFR and AT 1 R-Ab positivity were significantly associated with accelerated graft function decline. Conclusions. Serum AT 1 R-Ab positivity in the context of an indication biopsy >1 year post-transplant is associated with the
I N T R O D U C T I O N
Antibody-mediated rejection (ABMR) is the major cause of graft loss in both adult [1] [2] [3] and paediatric renal transplant recipients [3, 4] . The majority of these rejections are caused by preformed and/or de novo donor-specific antibodies against human leucocyte antigen donor-specific antibodies (HLA-DSA). However, there is a significant subset of patients with histological features of ABMR in the graft biopsy in whom HLA-DSA cannot be detected in the circulation despite the use of highly sensitive assays such as the single-antigen bead (SAB) technology. In recent years, therefore, there have been increasing efforts directed towards the detection and biological characterization of antibodies against other endothelial targets beside HLA [5] . Newly developed solid-phase assays enable the detection of functional non-HLA antibodies targeting G protein-coupled receptors such as the angiotensin II type 1 receptor. In one study of 63 HLA-DSAnegative adult patients, the presence of angiotensin II type 1 receptor antibodies (AT 1 R-Ab) was strongly associated with ABMR [6] . In a large prospective study in 599 kidney transplant recipients, the pre-transplant positivity for AT 1 R-Ab was an independent risk factor for allograft loss [7] . More recent smaller studies have confirmed the increased rejection risk in kidney transplant recipients with preformed AT 1 R-Ab [8, 9] and its link to a C4d-negative ABMR phenotype [10] . However, findings from adult populations cannot necessarily be extrapolated to paediatric patients. There are unique differences in the immune system in children, namely the naivety of their immune system and differences in alloimmunological reactivity, as reflected by small numbers of antigen-experienced T cells, mature dendritic cells or macrophages and HLA-alloreactive B cells [11] . Up to now, data on AT 1 R-Ab in paediatric renal transplant recipients have been scarce, from small descriptive case series [12] [13] [14] . The aims of this study were to investigate the association of serum AT 1 R-Ab with specific histological lesions and with graft function and survival in paediatric patients undergoing graft biopsies >1 year post-transplant for clinical indication. Targets of AT 1 RAb are constitutively expressed on the vascular endothelium and expression may be induced or increased during inflammatory events. Analysis of the phenotypic characteristics of biopsies in the presence of AT 1 R-Ab could provide further evidence linking them to allograft dysfunction. Because AT 1 R-Ab may exert pathophysiologic effects alone or in synergy with HLA antibodies, we analysed serum AT 1 R-Ab in conjunction with overall and complement-binding donor-specific HLA-DSA.
M A T E R I A L S A N D M E T H O D S

Study design and patient population
This is a retrospective single-centre cohort analysis based on prospectively collected serum samples of all paediatric patients 18 years of age at the date of transplantation who were nonpresensitized [HLA antibodies negative on complementdependent cytotoxicity (CDC) and enzyme-linked immunosorbent assay (ELISA) testing], received a kidney transplant at our institution between January 1999 and January 2010 and underwent a kidney graft biopsy for clinical indication (functional impairment or severe de novo proteinuria) >1 year posttransplant (index biopsy). Only patients with index biopsies after January 2004 were included, when routine C4d staining was introduced in our institution. T-or B-cell crossmatch-positive patients and recipients of ABO-incompatible or combined organ transplants were excluded from the analysis. In all, eight patients who met the inclusion criteria were secondarily excluded due to insufficient amounts of serum available or loss of follow-up. Therefore 62 of 70 eligible patients were analysed. Patient and transplant characteristics at the time of index biopsy are depicted in Table 1 and parameters at the time of engrafting are shown in Table 2 . Serum HLA-DSA and AT1R-Ab were measured at the time of index biopsy. Serum was collected in the framework of the ongoing prospective Collaborative Transplant Study (CTS) Serum Project. Data on C1q-fixing DSA in this cohort have been published previously [16] . Ethics committee approval was obtained and investigations were performed in accordance with the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines. Written informed consent was obtained by all parents or guardians and patients when appropriate for their age. This study was designed, analysed and reported according to the Strengthening the Reporting of Observational Studies in Epidemiology guidelines [17] .
Detection of HLA-DSA and AT1R antibodies
Patient sera were tested for the presence of AT 1 R-Ab using a quantitative ELISA (CellTrend, Luckenwalde, Germany). All sera were also analysed for HLA antibodies using LABScreen Luminex kits (One Lambda, Canoga Park, CA, USA). For highresolution typing of patients and their respective organ donors, polymerase chain reaction-sequence specific primers (SSP) Tray and Sequence kits (CTR, Heidelberg, Germany) and SSP kits (Olerup, Saltsjöbaden, Sweden) were used. DSA was determined against mismatched donor alleles from HLA-A, -B, -C, -DRB1, -DRB3, -DRB4, -DRB5, -DQA1, -DQB1 and -DPB1 loci and a mean fluorescence intensity (MFI) !500 was considered positive [18] .
Blood pressure and estimated glomerular filtration rate (eGFR) analysis Systolic and diastolic blood pressures were derived from casual office blood pressure measurements (average of three measurements taken within 5 min) by oscillometry obtained at the time of index biopsy and at three to five outpatient department visits prior to index biopsy and converted to z-scores based on reference data [19] . Arterial hypertension was defined as systolic and/or diastolic blood pressure >1.96 z-score (95th percentile). Graft function was assessed using eGFR according to the Schwartz formula [15] .
Immunosuppressive regimen
The initial immunosuppressive therapy is depicted in Table 2 . None of the patients received anti-thymocyte globulin or rituximab as induction therapy or prior to index biopsy. The immunosuppressive therapy at the time of index biopsy is depicted in Table 1 . Three patients received the mammalian target of rapamycin (mTOR) inhibitor sirolimus without a calcineurin inhibitor (CNI) due to severe CNI-induced chronic nephrotoxicity in a previous biopsy. A total of 23 patients (37%) were treated with a corticosteroid-free immunosuppressive regimen. Patients with T-cell-mediated allograft rejection (TCMR) of Banff type I or II were treated with methylprednisolone pulse therapy. Patients with biopsy-proven chronic ABMR received anti-humoral rejection therapy as previously described [20] . None of the patients received intravenous immunoglobulin G during a period of at least 3 months prior to measurement of AT 1 R-Ab.
Histopathology and C4d staining
Renal biopsies were carried out as indication biopsies due to an increase of serum creatinine (>20% above baseline without an alternative explanation) and/or de novo persistent proteinuria >100 g protein/mol creatinine. All biopsy specimens were graded using the Banff 2009-15 criteria [21] . Immunohistochemistry for C4d was performed on paraffin sections using a polyclonal antibody (C4dpAb; Bio-medica, Vienna, Austria).
Statistical analysis
Analyses were performed using Predictive Analytics Software (SPSS) Statistics 22.0 (IBM, Armonk, NY, USA) and Statistical Analysis Software 9.3 (SAS Institute, Cary, NC, USA). Unless stated otherwise, results for continuous variables are presented mean 6 SD or as median with interquartile range (IQR). Differences between groups were analysed with one-way analysis of variance (ANOVA), Student's t-test or, if normality failed, with Kruskal-Wallis or Mann-Whitney U rank-sum test. For categorical data, Pearson chi-square tests were used. Receiver operating characteristic (ROC) plots were generated and area under the curve (AUC) and 95% confidence interval (CI) limits were calculated using the method of Hanley and McNeil [22] . Cox proportional hazards regression analysis and Kaplan-Meier survival analysis were used for time-to-event analyses from index biopsy and tested for significance with the two-sided log-rank test. For multivariable Cox regression models, a forward stepwise selection method was used, with a significance level of P < 0.1 for entering a variable into the model and P ! 0.2 for removal of a previously selected variable. P < 0.05 was regarded as statistically significant in a descriptive sense.
R E S U L T S
Patient characteristics
Patient, donor and transplant characteristics at the time of transplantation are given in Table 2 . Baseline characteristics at the time of index biopsy were in general comparable among these three groups, with the exception that patients with ABMR less frequently received a tacrolimus (TAC)-based maintenance immunosuppressive regimen than patients with normal biopsy results or patients with TCMR (50.0% versus 84.2% versus 73.3%; P ¼ 0.041) and that the proportion of patients with proteinuria was higher in the ABMR group (67.9% versus 26.3% versus 33.3%; P ¼ 0.010; Table 1 ). Index biopsies in the ABMR group tended to be performed somewhat later post-transplant (P ¼ 0.067; Table 1 ).
Serum AT 1 R-Ab stratified according to graft biopsy results
Investigating the differences in AT 1 R-Ab serum concentrations among these three groups revealed significantly higher values in the ABMR group [12. To determine the optimal AT 1 R-Ab cut-off value discriminating between patients with features of ABMR in the biopsy and those without (no rejection group and TCMR group), ROC curve analyses were performed. An area under the ROC curve value of 0.74 (95% CI 0.61-0.87; P ¼ 0.001) indicated a moderate discriminative capacity (Figure 2) . Based on the Youden Index (maximization of sensitivity and specificity), the ideal cut-off value for AT 1 R-Ab was determined as 9.5 U/mL, resulting in a sensitivity of 79% and a specificity of 71%. Using this cut-off value, 4 of 28 patients (14.3%) with ABMR in the index biopsy were positive only for HLA-DSA, 6 patients (21.4%) were positive only for AT 1 R-Ab and 16 patients (57.1%) were double positive for both HLA-DSA and AT 1 R-Ab.
AT 1 R-Ab levels were significantly higher in the group with concomitant HLA-DSA positivity compared with HLA-DSA-negative patients [12. significantly between HLA-DSA-positive patients with or without HLA-DSA C1q positivity (P ¼ 0.407). There was no correlation between AT 1 R-Ab levels and HLA-DSA MFI values (P ¼ 0.815).
Next, we compared the biopsy scores with respect to AT 1 RAb and HLA-DSA status. AT 1 R-Ab levels were significantly higher in patients with a peritubular capillaritis (PTC) score >1 in the index graft biopsy compared with patients with a PTC score of 0 [9.0 U/mL (IQR 7.0-14.0) versus 12.0 (IQR 11.0-19.0); P ¼ 0.041; Figure 3 ], while AT 1 R-Ab levels were not significantly altered in patients with different Banff i (P ¼ 0.521) or t scores (P ¼ 0.503). Patients with AT 1 R-Ab and HLA-DSA double positivity had a significantly higher microvascular inflammation score [1.0 (IQR 0-2.0)], defined as the sum of glomerulitis and PTC, than DSA-negative patients [0 (IQR 0-0.5); P ¼ 0.004]. C4d positivity was less frequently observed in the cohort that was DSA negative and AT 1 R-Ab positive (25%; P ¼ 0.154) than in the cohort that was DSA positive and AT 1 R-Ab negative (44.4%) or in the cohort that was both DSA positive and AT 1 R-Ab positive (50%; Supplementary data, Table S1 ), but the numbers were too small for a meaningful comparison.
Graft survival, graft function and blood pressure according to AT 1 R-Ab status
Patient characteristics at the time of transplantation were comparable between the AT 1 R-Ab-positive and -negative groups (Table 2) . However, at the time of index biopsy, significantly more AT 1 R-Ab-positive patients showed additional HLA-class II DSA positivity (P ¼ 0.002). AT 1 R-Ab positivity was associated with a significantly worse graft survival (P ¼ 0.025) and a significantly more rapid decline of graft function (P ¼ 0.004) during an observation period of up to 5 years post-biopsy ( Figure 4 , upper and lower panels). The 5-year graft survival was only 59% in the AT 1 R-Ab-positive group compared with 87% in the AT 1 R-Ab-negative group. Considering the eGFR decline in the time period of 5 years post-biopsy, 61% of AT 1 R-Ab-positive patients revealed an eGFR decline !50% of baseline compared with only 20% of AT 1 R-Ab-negative patients.
In AT 1 R-Ab-positive patients, systolic but not diastolic blood pressure z-scores averaged over three to five office blood pressure measurements prior to index biopsy were significantly higher than in AT 1 R-Ab-negative patients (P ¼ 0.046; Table 3 ). Of note, the total amount of prescribed anti-hypertensive drugs at the time of the index biopsy and the number of patients on an angiotensin II receptor blocker were comparable between these two groups (Table 3) .
Graft survival and function according to AT 1 R-Ab and HLA-DSA status
To further investigate the impact of both AT 1 R-Ab and HLA-DSA on graft survival and function, patients were divided into groups depending on their AT 1 R-Ab and HLA-DSA status. Baseline patient characteristics at the time of index biopsy were comparable among these three groups: patients without DSA, patients with AT 1 R-Ab only and patients with double positivity of AT 1 R-Ab and HLA-DSA (Supplementary data, Table S1 ). AT 1 R-Ab-positive (n ¼ 12) as well as AT 1 R-Ab and HLA-DSA AT 1 R-Ab levels were significantly increased in patients with a PTC score of 2 compared with patients with a PTC score of 0.
AT 1 R antibodies in paediatric renal transplantation double-positive patients (n ¼ 20) more often experienced an eGFR decline !50% of baseline than DSA-negative patients (n ¼ 21; P ¼ 0.026 and P ¼ 0.001 log-rank test; Figure 5 ). Patients with AT 1 R-Ab and HLA-DSA double positivity had a more rapid eGFR decline than patients who were only positive for AT 1 R-Ab or HLA-DSA (n ¼ 9), but this difference did not reach statistical significance (P ¼ 0.231), most likely due to the small number of observations.
Risk factors for graft function deterioration
We analysed non-invasive risk factors such as immunological and biochemical biomarkers for graft function deterioration, defined as an eGFR decline !50% of baseline. HLA-DSA (further differentiated according to C1q-complement binding capacity), AT 1 R-Ab status, eGFR at the time of index biopsy, proteinuria and arterial hypertension were assessed in a multivariate Cox regression model including age at index biopsy and time period from transplantation to index biopsy. In this model, C1q-positive HLA-DSA, eGFR and AT 1 R-Ab positivity were significantly associated with more rapid graft function decline (Table 4A ). When we added histological characteristics such as transplant glomerulopathy and C4d status to this risk factor analysis, only transplant glomerulopathy, C1q-positive HLA-DSA and eGFR at the time of index biopsy remained statistically significant in the multivariate analysis (Table 4B) .
D I S C U S S I O N
This is the first study in paediatric renal transplant recipients that analysed the prognostic significance of serum AT 1 R-Ab in conjunction with other known risk factors for graft failure in a carefully phenotyped single-centre cohort. The main result of this study is that the presence of AT 1 R-Ab in the context of a late (>1 year post-transplant) indication biopsy identifies a subgroup of patients with a more rapid subsequent eGFR decline. In the multivariate Cox regression model of non-invasive risk factors associated with enhanced graft function deterioration, AT 1 R-Ab positivity [adjusted hazard ratio (HR) 2.83] was the second strongest independent predictor of adverse graft outcome after the parameter C1q-positive DSA (HR 5.98). We also observed that serum AT 1 R-Ab concentrations were significantly higher in patients with biopsy-proven ABMR than in patients with TCMR or no rejection, consistent with recent findings in adult renal transplant recipients [23] . It is noteworthy that in our study a relevant subset of patients (21.4%) with features of ABMR in the index biopsy was only positive for AT 1 R-Ab and not for HLA-DSA. Hence, from these and other data it appears advisable to test patients with ABMR not only for the presence of HLA-DSA, but also for non-HLA antibodies against endothelial targets such as AT 1 R-Ab.
The question arises whether AT 1 R-Ab directly induces or promotes ABMR or is an epiphenomenon of endothelial injury. While these two possibilities cannot easily be differentiated in a clinical study, experimental data indicate a direct effect of AT 1 R-Ab on endothelial injury, inflammation and allograft dysfunction [24, 25] . AT 1 R, the target for AT 1 R-Ab, is expressed at high levels on endothelial cells, and activation of this receptor in human microvascular endothelial cells in the presence of AT 1 R-Ab causes endothelial cell dysfunction and neutrophil migration; these effects were reduced in the presence of an angiotensin receptor blocker [24] . Therefore, AT 1 R-Ab is thought to contribute to graft dysfunction by inducing activation of signalling pathways in a similar fashion as the endogenous ligand for this receptor, angiotensin II [24] [25] [26] . In addition, experimental data indicate that activation of AT 1 R leads to an upregulation of HLA class II antigens on endothelial cells [27] . This experimental finding corresponds with our observation that patients with AT 1 R-Ab and HLA-DSA double positivity had a higher vascular micro-inflammation score and more rapid graft function deterioration than DSA-negative patients. 
Characteristics
Entire cohort (n ¼ 62) Our study extends the observations of Philogene et al. [23] , because we also investigated the prognostic significance of AT 1 R-Ab positivity regarding graft function and survival. The 5-year graft survival was only 59% in the AT 1 R-Ab-positive group compared with 87% in the AT 1 R-Ab-negative group. In the time period of 5 years post-biopsy, 61% of AT 1 R-Abpositive patients revealed an eGFR decline !50% of baseline compared with only 20% of AT 1 R-Ab-negative patients. Furthermore, patients with AT 1 R-Ab and HLA-DSA double positivity tended to have a more pronounced decline of graft function than patients who were only positive for AT 1 R-Ab or HLA-DSA. As outlined above, double positivity for AT 1 R-Ab and HLA-DSA appears to enhance the histopathological lesions of ABMR associated with more rapid graft function decline, but further studies in larger patient populations are required to confirm this hypothesis.
We determined an optimal AT 1 R-Ab cut-off value of 9.5 U/ mL discriminating between patients with or without features of ABMR in the biopsy. Three previous studies investigating AT 1 R-Ab levels in renal transplant recipients have suggested a similar threshold for positivity [6, 7, 28] . Giral et al. [7] observed that pre-transplant sensitization against AT 1 R is a risk factor for acute rejection and graft loss in adult patients and determined, by use of the same assay as in our study, a threshold of AT 1 R-Ab levels at 10 U/mL based on a statistical analysis using the Hothorn and Zeileis method [29] . Lee et al. [8] calculated an optimal cut-off value for pre-transplant AT 1 R-Ab of 9.05 U/mL for the risk prediction of acute rejection in the first year post-transplant in Asian adult renal transplant recipients. While it is interesting that these cut-off values are well comparable among different patient populations and age groups, further studies of AT 1 R-Ab both in the pre-and post-transplant setting are required to firmly establish valid cut-off values for AT 1 R-Ab positivity.
Only two previous studies [12, 13] and one case report [14] have reported on AT 1 R-Ab serum concentrations in paediatric renal transplant recipients. A small study (n ¼ 29) reported that 40% of patients developed AT 1 R-Ab in the first year posttransplant, but AT 1 R-Ab did not correlate with worse clinical outcomes [12] . Bjerre et al. [13] reported in a cross-sectional study of 30 children that AT 1 R-Ab levels were significantly higher in stable paediatric versus adult renal transplant recipients and higher compared with controls of comparable age groups, but they did not analyse the relationship of serum AT 1 R-Ab with outcome measures such as graft histology, function or survival. One case report described a girl with accelerated acute C4d-positive kidney transplant rejection, malignant hypertension, encephalopathy and the presence of both AT 1 RAb and HLA class II antibodies [14] .
The strength of our study is that it was based on a prospective protocol investigating a paediatric patient cohort at an increased risk of graft deterioration reflected by a clinically indicated graft biopsy >1 year post-transplant. A limitation is the relatively small number of patients investigated, but this is an inherent problem for all studies in the paediatric renal transplant population. Furthermore, AT 1 R-Ab was measured only at a single time point post-transplant. Future studies will have to evaluate whether longitudinal analyses of AT 1 R-Ab in an unselected patient cohort of paediatric kidney allograft recipients is a surrogate marker for increased immunological risk requiring more intense immunosuppressive therapy. It will also be important to investigate the effect of potential treatment modalities on AT 1 R-Ab and if they improve outcomes for these patients.
In conclusion, the presence of AT 1 R-Ab in the context of an indication biopsy >1 year post-transplant is associated with the histopathology of ABMR and is a non-invasive risk factor for subsequent accelerated graft function decline. Hence the determination of serum AT 1 R-Ab may enhance the predictive value of HLA-DSA and/or C1q-binding DSA. Screening for AT 1 RAb in conjunction with HLA-DSA at regular intervals posttransplant may have the potential to identify patients at high risk for ABMR, in whom targeted enhancement of immunosuppressive therapy may improve transplant outcome. This is especially relevant for the paediatric kidney transplant Table 4 . Risk factor analysis for graft deterioration (eGFR <50% of baseline prior to index biopsy) up to 5 years post-biopsy
Risk factors
Unadjusted HR (95% CI) AT 1 R antibodies in paediatric renal transplantation population, in whom, in the light of their long life expectancy, preservation of good graft function is of utmost importance.
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